NASDAQ
Freenome, Inc. (FRNM)
♥ 401 Thanks from members
Freenome Holdings, Inc. successfully debuted on the Nasdaq under ticker FRNM following a SPAC merger netting $310.3M, closely followed by a major U.S. FDA approval for its blood-based colorectal cancer screening test developed in collaboration with Abbott.